SC
SYRE icon

Samlyn Capital’s Spyre Therapeutics SYRE Stock Holding History

Samlyn Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.5M Buy
400,075
+3,414
+0.9% +$249K 0.58% 53
2026
Q1 		$20M Buy
+396,661
New +$15M 0.34% 64

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Samlyn Capital's SYRE Position: Q2 2026 in Review

Samlyn Capital increased its Spyre Therapeutics (SYRE) stake by 0.86% in Q2 2026, buying an estimated $249K and bringing the position to 400,075 shares worth $35.5M. The position accounts for 0.58% of the portfolio, ranked #53.

Samlyn Capital first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Samlyn Capital held 400,075 shares of Spyre Therapeutics worth $35.5M as of Q2 2026.
  • Samlyn Capital bought 3,414 Spyre Therapeutics shares in Q2 2026, an estimated $249K.
  • Spyre Therapeutics made up 0.58% of Samlyn Capital's portfolio in Q2 2026, its #53 holding.
  • Samlyn Capital first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Samlyn Capital's 13F filing for Q2 2026, filed 14 Aug 2026.